Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer

1 Feb 2025

Abstract excerpt

Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer with limited treatment options. Patients often respond well to initial chemo-immunotherapy but relapse quickly, necessitating new strategies to enhance immune responsiveness. Recent research explores combining DNA-damaging therapies with immunotherapy to activate the STING pathway and improve the antitumor immune response. The addition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Lung Cancer Research Studies
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40034862
DOI: 10.1016/j.isci.2025.111943

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerPMID 40034862Read ↗

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerSemantic proximity Read ↗

Small cell lung cancer: Novel treatments beyond immunotherapySemantic proximity Read ↗

Targeting the DNA Damage Response Machinery for Lung Cancer TreatmentSemantic proximity Read ↗

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a reviewSemantic proximity Read ↗

PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve ResponsesSemantic proximity Read ↗

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.Semantic proximity Read ↗

Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathwaySemantic proximity Read ↗

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translationSemantic proximity Read ↗

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerSemantic proximity Read ↗

Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancerSemantic proximity Read ↗

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.Semantic proximity Read ↗

PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.